The White House announced Monday that nine more drug manufacturers, including Teva, Sun Pharma, and Astellas, have agreed to cap their U.S. prices at whatever they charge in other wealthy countries. That brings the total number of companies in this program to 26, and the administration says those companies now account for roughly 89 percent of the branded drug market in the United States. None of the nine new companies build their business primarily around psychiatric drugs; Teva does sell one, a long-acting antipsychotic called Uzedy, but it is a small piece of a company built mostly on generics. That almost doesn’t matter, because this program has already grown large enough to reach nearly everyone in the industry, psychiatric drugmakers included, without ever needing to name them specifically.
What a most-favored-nation deal does
The idea is simple to state: a company agrees not to charge American patients more than it charges patients in other developed countries for the same drug. President Trump signed an executive order setting this policy in motion in May 2025, then sent letters to 17 major pharmaceutical companies that July telling them what he wanted. All 17 eventually signed on. Monday’s nine additions are the next wave, smaller and mid-sized manufacturers rather than the industry’s largest names.
Why psychiatric drugs are already covered, even though nobody named them
Johnson & Johnson, which makes esketamine, the nasal-spray antidepressant sold as Spravato, is one of the original 17 companies, not one of Monday’s nine. That means any pricing pressure this creates for esketamine has existed for months already; today’s news doesn’t change that specific exposure. What today’s announcement shows is how far this policy has spread since then. When 26 companies cover 89 percent of the branded market, a company that makes a psychiatric drug and hasn’t signed a deal yet is now the exception, not the rule. Any company still developing a new psychiatric drug toward approval, and there are several this desk tracks closely, has to assume its eventual U.S. launch price will be judged against this standard, whether or not it has personally signed anything yet.
The part that should give any investor pause
These are voluntary agreements, not a law. There’s no enforcement mechanism requiring a company to honor the pricing cap it agreed to, and Congress hasn’t passed anything making these deals binding, though Trump has publicly called for exactly that. In March, senior Democrats on the House and Senate committees that oversee healthcare policy wrote directly to the White House asking to see the actual terms of these agreements, terms they said had been kept from Congress and the public entirely. The administration reportedly told companies not to disclose the details themselves. A patient advocacy group’s response to Monday’s announcement made a similar point: many of these deals apply specifically to Medicaid, where steep discounts already existed before any of this started, and states get to choose whether to participate at all. None of that means the arrangement is fake or that it won’t eventually matter. It means a company’s public agreement to “most-favored-nation pricing” and that pricing reaching a patient’s pharmacy counter are two different things right now, and the gap between them is where the real uncertainty sits.
What this means for how a psychiatric drug’s launch gets priced
Every company approaching FDA approval for a new psychiatric drug now has to build its U.S. pricing model around this standard as a base assumption, not a risk sitting off in the distance. That’s a real shift in how launch economics get modeled, even before any specific enforcement exists. A branded drug with no generic competition, which describes most of the pipeline assets in psychedelic and next-generation psychiatric drug development, is squarely the kind of product this policy is built to constrain. Generic and off-patent drugs are largely untouched by any of this.
What to watch next
Two things will tell you whether this program has real teeth or stays a voluntary gesture: whether Congress ever passes legislation making these agreements binding, and whether any company that signed a deal ends up in a public dispute over whether it’s honoring the price it agreed to. Neither has happened yet. Until one does, every company operating under one of these 26 deals is making a bet that the administration’s goodwill, and its own public commitment, will hold up better than a law would, and every company still outside the program is betting it can avoid this pressure a while longer.